Synergy Pharmaceuticals Appoints Paul Eng, Ph.D., As Senior Vice President, Drug Development

Synergy Pharmaceuticals Appoints Paul Eng, Ph.D., As Senior Vice President, Drug Development

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the appointment of Paul Eng, Ph.D., as Senior Vice President, Drug Development. Dr. Eng will lead all clinical development operations for Synergy's pivotal phase 3 program with plecanatide in patients with irritable bowel syndrome with constipation (IBS-C). 

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.